ReviewInternational journal of nanomedicine2013
Particle platforms for cancer immunotherapy.
Review in International journal of nanomedicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 56 citations in OpenAlex.
- Neoantigen Identification and Dendritic Cell-Based Vaccines for Lung Cancer Immunotherapy.Vaccines · 2024Review
- Nanomaterials for Protein Delivery in Anticancer Applications.Pharmaceutics · 2021Review
- Nano and Microparticle Emerging Strategies for Treatment of Autoimmune Diseases: Multiple Sclerosis and Type 1 Diabetes.Advanced healthcare materials · 2020Review
- Interaction of Immune Cells and Tumor Cells in Gold Nanorod-Gelatin Composite Porous Scaffolds.Nanomaterials (Basel, Switzerland) · 2019Article
- Enhanced anti-tumor immunotherapy by silica-coated magnetic nanoparticles conjugated with ovalbumin.International journal of nanomedicine · 2019Article
- Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy.PloS one · 2018Article
- Polyelectrolyte-Enrobed Cancer Cells in View of Personalized Immune-Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2017Article
- Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy.Frontiers in immunology · 2017Review
- Development and Evaluation of Biodegradable Particles Coloaded With Antigen and the Toll-Like Receptor Agonist, Pentaerythritol Lipid A, as a Cancer Vaccine.Journal of pharmaceutical sciences · 2016Article
- Article
- Polymer nanoparticles for cross-presentation of exogenous antigens and enhanced cytotoxic T-lymphocyte immune response.International journal of nanomedicine · 2016Article
- Adjuvants for peptide-based cancer vaccines.Journal for immunotherapy of cancer · 2016Review
- Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy.International journal of nanomedicine · 2015Article
- Biodegradable polymeric microsphere-based vaccines and their applications in infectious diseases.Human vaccines & immunotherapeutics · 2015Review
- Nanocarrier-based immunotherapy in cancer management and research.ImmunoTargets and therapy · 2014Review
- Article
- Porous silicon advances in drug delivery and immunotherapy.Current opinion in pharmacology · 2013Review
- Nanoparticle-based vaccine delivery for cancer immunotherapy.Immune network · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated understanding and respect for the relevance of the immune system in cancer development and therapy has led to increased development of immunotherapeutic regimens that target existing cancer cells and provide long-term immune surveillance and protection from cancer recurrence. This review discusses using particles as immune adjuvants to create vaccines and to augment the anticancer effects of conventional chemotherapeutics. Several particle prototypes are presented, including liposomes, polymer nanoparticles, and porous silicon microparticles, the latter existing as either single- or multiparticle platforms. The benefits of using particles include immune-cell targeting, codelivery of antigens and immunomodulatory agents, and sustained release of the therapeutic payload. Nanotherapeutic-based activation of the immune system is dependent on both intrinsic particle characteristics and on the immunomodulatory cargo, which may include danger signals known as pathogen-associated molecular patterns and cytokines for effector-cell activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.